243 related articles for article (PubMed ID: 36157542)
1. Mechanistic and functional extrapolation of SET and MYND domain-containing protein 2 to pancreatic cancer.
Alshammari E; Zhang YX; Yang Z
World J Gastroenterol; 2022 Aug; 28(29):3753-3766. PubMed ID: 36157542
[TBL] [Abstract][Full Text] [Related]
2. Coordination of stress signals by the lysine methyltransferase SMYD2 promotes pancreatic cancer.
Reynoird N; Mazur PK; Stellfeld T; Flores NM; Lofgren SM; Carlson SM; Brambilla E; Hainaut P; Kaznowska EB; Arrowsmith CH; Khatri P; Stresemann C; Gozani O; Sage J
Genes Dev; 2016 Apr; 30(7):772-85. PubMed ID: 26988419
[TBL] [Abstract][Full Text] [Related]
3. Biochemical characterization of human SET and MYND domain-containing protein 2 methyltransferase.
Wu J; Cheung T; Grande C; Ferguson AD; Zhu X; Theriault K; Code E; Birr C; Keen N; Chen H
Biochemistry; 2011 Jul; 50(29):6488-97. PubMed ID: 21678921
[TBL] [Abstract][Full Text] [Related]
4. Histone methyltransferase SMYD2: ubiquitous regulator of disease.
Yi X; Jiang XJ; Fang ZM
Clin Epigenetics; 2019 Aug; 11(1):112. PubMed ID: 31370883
[TBL] [Abstract][Full Text] [Related]
5. The tale of two domains: proteomics and genomics analysis of SMYD2, a new histone methyltransferase.
Abu-Farha M; Lambert JP; Al-Madhoun AS; Elisma F; Skerjanc IS; Figeys D
Mol Cell Proteomics; 2008 Mar; 7(3):560-72. PubMed ID: 18065756
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic upregulation of MNAT1 by SMYD2 is linked to PI3K/AKT activation and tumorigenesis of pancreatic adenocarcinoma.
Xu Z; Liu Y; Pan Z; Qin L
Histol Histopathol; 2024 Feb; 39(2):263-277. PubMed ID: 37232506
[TBL] [Abstract][Full Text] [Related]
7. Structural insights into estrogen receptor α methylation by histone methyltransferase SMYD2, a cellular event implicated in estrogen signaling regulation.
Jiang Y; Trescott L; Holcomb J; Zhang X; Brunzelle J; Sirinupong N; Shi X; Yang Z
J Mol Biol; 2014 Oct; 426(20):3413-25. PubMed ID: 24594358
[TBL] [Abstract][Full Text] [Related]
8. Conformational Dynamics of Lysine Methyltransferase Smyd2. Insights into the Different Substrate Crevice Characteristics of Smyd2 and Smyd3.
Chandramouli B; Chillemi G
J Chem Inf Model; 2016 Dec; 56(12):2467-2475. PubMed ID: 27959541
[TBL] [Abstract][Full Text] [Related]
9. Identification and characterization of Smyd2: a split SET/MYND domain-containing histone H3 lysine 36-specific methyltransferase that interacts with the Sin3 histone deacetylase complex.
Brown MA; Sims RJ; Gottlieb PD; Tucker PW
Mol Cancer; 2006 Jun; 5():26. PubMed ID: 16805913
[TBL] [Abstract][Full Text] [Related]
10. Structure of human lysine methyltransferase Smyd2 reveals insights into the substrate divergence in Smyd proteins.
Xu S; Zhong C; Zhang T; Ding J
J Mol Cell Biol; 2011 Oct; 3(5):293-300. PubMed ID: 21724641
[TBL] [Abstract][Full Text] [Related]
11. Effects of SMYD2-mediated EML4-ALK methylation on the signaling pathway and growth in non-small-cell lung cancer cells.
Wang R; Deng X; Yoshioka Y; Vougiouklakis T; Park JH; Suzuki T; Dohmae N; Ueda K; Hamamoto R; Nakamura Y
Cancer Sci; 2017 Jun; 108(6):1203-1209. PubMed ID: 28370702
[TBL] [Abstract][Full Text] [Related]
12. Targeting SMYD2 inhibits angiogenesis and increases the efficiency of apatinib by suppressing EGFL7 in colorectal cancer.
Zhang Y; Zhou L; Xu Y; Zhou J; Jiang T; Wang J; Li C; Sun X; Song H; Song J
Angiogenesis; 2023 Feb; 26(1):1-18. PubMed ID: 35503397
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of SET and MYND domain-containing protein 2 (
Zhang P; Ruan J; Weng W; Tang Y
Leuk Lymphoma; 2020 Feb; 61(2):437-444. PubMed ID: 31612757
[TBL] [Abstract][Full Text] [Related]
14. Central role of Yes-associated protein and WW-domain-containing transcriptional co-activator with PDZ-binding motif in pancreatic cancer development.
Rozengurt E; Eibl G
World J Gastroenterol; 2019 Apr; 25(15):1797-1816. PubMed ID: 31057295
[TBL] [Abstract][Full Text] [Related]
15. Regulation of EZH2 by SMYD2-Mediated Lysine Methylation Is Implicated in Tumorigenesis.
Zeng Y; Qiu R; Yang Y; Gao T; Zheng Y; Huang W; Gao J; Zhang K; Liu R; Wang S; Hou Y; Yu W; Leng S; Feng D; Liu W; Zhang X; Wang Y
Cell Rep; 2019 Nov; 29(6):1482-1498.e4. PubMed ID: 31693890
[TBL] [Abstract][Full Text] [Related]
16. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
[TBL] [Abstract][Full Text] [Related]
17. SETD8 potentiates constitutive ERK1/2 activation via epigenetically silencing DUSP10 expression in pancreatic cancer.
Liu M; Qin Y; Hu Q; Liu W; Ji S; Xu W; Fan G; Ye Z; Zhang Z; Xu X; Yu X; Zhuo Q
Cancer Lett; 2021 Feb; 499():265-278. PubMed ID: 33232789
[TBL] [Abstract][Full Text] [Related]
18. Oncogenic ERBB2 aberrations and KRAS mutations cooperate to promote pancreatic ductal adenocarcinoma progression.
Li Z; Shao C; Liu X; Lu X; Jia X; Zheng X; Wang S; Zhu L; Li K; Pang Y; Xie F; Lu Y; Wang Y
Carcinogenesis; 2020 Mar; 41(1):44-55. PubMed ID: 31046123
[TBL] [Abstract][Full Text] [Related]
19. Ectopic HOTTIP expression induces noncanonical transactivation pathways to promote growth and invasiveness in pancreatic ductal adenocarcinoma.
Wong CH; Li CH; He Q; Chan SL; Tong JH; To KF; Lin LZ; Chen Y
Cancer Lett; 2020 May; 477():1-9. PubMed ID: 32120024
[TBL] [Abstract][Full Text] [Related]
20. Lysine methyltransferase SMYD2 promotes triple negative breast cancer progression.
Li LX; Zhou JX; Calvet JP; Godwin AK; Jensen RA; Li X
Cell Death Dis; 2018 Feb; 9(3):326. PubMed ID: 29487338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
